Item 7.01 Regulation FD Disclosure. On July 8,
Post# of 72446
Posted On: 07/08/2016 9:55:30 AM
Re: grizzlyman #24994
Item 7.01 Regulation FD Disclosure.
On July 8, 2016, Cellceutix Corporation (the "Company"
released its non-confidential presentation ("Slides" to its shareholders regarding the Company's dermatological programs. The Slides are posted on the Company's website, and titled "Dermatology Overview," at http://www.cellceutix.com and navigating to "Events and Presentations".
The Company's non-confidential presentation is distinguished from its confidential presentation, which is presented to potential partnering companies upon signing a non-disclosure agreement.
By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.
The information contained in the Slides is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission ("SEC" filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.
The information presented in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act" , or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered "filed" under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
On July 8, 2016, Cellceutix Corporation (the "Company"
released its non-confidential presentation ("Slides" to its shareholders regarding the Company's dermatological programs. The Slides are posted on the Company's website, and titled "Dermatology Overview," at http://www.cellceutix.com and navigating to "Events and Presentations". The Company's non-confidential presentation is distinguished from its confidential presentation, which is presented to potential partnering companies upon signing a non-disclosure agreement.
By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.
The information contained in the Slides is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission ("SEC"
filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure. The information presented in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"
, or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered "filed" under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act. 
(0)
(0)